Radiation therapy is a highly effective tool for treating all stages of prostate cancer (PCa), from curative approaches in localized disease to palliative care and enhanced survival for patients with distant bone metastases. The therapeutic index of these approaches may be enhanced with targeted radiation-sensitizing agents. Aptamers are promising nucleic-acid delivery agents for short interfering RNAs (siRNA) and short hairpin RNAs (shRNA). We have previously developed a radiation-sensitizing RNA aptamer-shRNA chimera which selectively delivers DNA-PK targeting shRNAs to 
INTRODUCTION
Ionizing radiation (IR) is a widely utilized tool in the management of prostate cancer (PCa) (1, 2) . External beam radiation therapy (EBRT) is applied to treat low-risk primary PCa as well as intermediate to high-risk primary PCa, in combination with androgen deprivation therapy or as an adjuvant after surgery.
EBRT or systemic radionuclides, such as strontium-89 or samarium-153, can further be utilized for the management of pain associated with PCa bone metastases. More recently, the bone seeking alpha-emitting particle, radium 223 dichloride, was shown to enhance the overall survival of men with castration resistant metastatic PCa to bone (3) . While IR therapy is commonly utilized and effective, the long-term benefits can be limited for some patients.
For example, the estimated ten year disease-free-survival rate for locally advanced PCa following IR therapy is less than 50% (4, 5) . The survival benefits of radium are also limited, providing only three months of additional survival in men who previously received standard chemotherapy (3) . Thus, there are several opportunities to improve IR therapies.
Improvements in IR therapy can be achieved through new mechanisms in delivery or dosing, or through IR-sensitizing strategies. Radiation sensitization is an attractive approach because it has the potential to either improve the potency of existing therapies, or to reduce the amount of IR required. Importantly, to improve the therapeutic index tumor-targeted or tumor-selective IR-sensitization is required, to spare healthy tissues from similar IR-sensitization (6) . Radiation therapy primarily causes DNA double-strand breaks (DSB), which are considered to be the most lethal lesion (7-9). A critical pathway of DSB repair is non-homologous end joining, which involves signaling through the DNA Protein Kinase (DNA-PK) complex (10). The catalytic subunit of DNA-PK was recently identified as one of the most potent targets for PCa IR-sensitization in a high throughput siRNA library screen (11).
In light of this we developed a DNA-PK-targeted radiation-sensitizing agent. Prostate-selective targeting was achieved through a previously developed PSMA-targeting RNA aptamer, A10-3 (12).
A short hairpin RNA (shRNA), targeting DNA-PK, was then affixed to the end of this aptamer, generating an internalizing aptamer-shRNA chimera (11,13). When these chimera were intratumorally administered into established PSMA-positive human xenograft tumors, the therapeutic effect of IR was significantly enhanced (11). While these results are promising, the clinical translation of this strategy may be challenging.
The chemical synthesis of long, 2'-modified RNA aptamers can be costly and are generally limited to a maximum product length of 50-60 nucleotides (14) .
Consequently, aptamer targeted therapeutics above this size have been generated by in vitro transcription (11,13). Recently, a truncated form of the A10-3 aptamer was identified and shown to be sufficiently small for chemical synthesis and targeted siRNA knock-down of Polo-like kinase 1 (15) . Intraperitoneal injection of these aptamer-siRNA chimera caused a pronounced regression of established PSMA-expressing tumors, revealing the potential for systemically administered PSMA aptamer-targeted siRNAs. In light of these results, and other successful systemic applications of aptamer-siRNAs (16, 17) , we sought to develop a chemically-synthesized aptamer-siRNA chimera for systemic PCa radiation sensitization. Here we describe the development and characterization of this chimera in a human PCa xenograft model of EBRT. 
MATERIALS AND METHODS

Materials
Immunoblotting.
Cells were lysed by Nupage LDS Sample Buffer (Life Tumor response was determined as reaching 4 times its volume at the start of treatment.
Immunohistochemistry.
Slides were deparaffinized, rehydrated and stained for DNA-PK as previously described (11 Table S2 ). Products were resolved by ethidium bromide stained agarose gel electrophoresis.
Statistical analysis. Tumor size was evaluated by two-way ANOVA. P value of 0.05 or less was considered significant. Extensions to tumor quadrupling: Events (tumor volume < 4 fold from injection) were plotted by Kaplan-Meier curve and analyzed by log-rank (Mantel-Cox) test. Paired samples were evaluated by student's t-test.
RESULTS
Chemically-synthesized aptamer-siRNA chimera. The A10-3-DNAPK-siRNA chimera was generated through a three-part chemical synthesis and annealing process (Fig 1A) . Previous truncations of the A10-3 aptamer had identified the 5'-terminal 39 nucleotides (nt) as the minimally functional region (15) .
We therefore hypothesized that a portion of the 3'-terminus of A10-3 was unnecessary and could be used as a 'bridge' to anneal radiation-sensitizing siRNAs. A similar approach has been successful with other aptamer-siRNA chimera (15, 20) . A complementary 'bridge' RNA oligonucleotide was designed by fusing the sense strand of the DNA-PK-targeting siRNA to a 13 nt extension with complementarity to the 3'-terminus of the aptamer (Fig 1A, AS-siRNA) . A dinucleotide uridine spacer was placed between the bridge and sense siRNA portions to mimic a 3'-overhang. A complementary anti-sense DNA-PK siRNA was then applied and also designed to contain a 3' dinucleotide uridine overhang (Fig 1A, S-siRNA) . Control chimera containing non-targeting aptamers (Neg-DNAPK) or non-specific siRNA (A10-3-Con)
were also generated using the same 'bridge' strategy as above (Supplementary Table   S1 ). The efficiency of generating the annealed aptamer-siRNA chimera is high, with over 90% efficiency (Fig 1B) . The chimera are functional substrates of Dicer, resulting in the desired siRNA product (Fig 1C) .
Aptamer-siRNAs knock-down DNA-PK and sensitize human PCa cells to IR.
Chemically synthesized and annealed aptamer-siRNA chimera were evaluated for the ability to knock-down DNA-PK and to sensitize PSMA expressing cells to IR. A previously developed PSMA-positive reporter cell line, LNCaP-MLuc, was applied for these studies (18) . Cells were treated with 400 nM of A10-3-DNAPK or a negative control chimera with non-specific siRNA (A10-3-Con), in the absence of transfection reagents, and relative DNA-PK expression levels were quantified by real less DNA-PK mRNA levels when compared to cells treated with A10-3-Con (Fig 2A) .
siRNA transfection was utilized as a positive control for these studies (Fig 2A,   siDNAPK) . Knock-down of DNA-PK protein was verified by immunoblotting ( Fig   2B) . 5'-rapid amplification of cDNA ends (5'-RACE) was then applied to verify that DNA-PK knock-down was mediated by RNAi-induced mRNA cleavage, as detected by the predicted cleavage product (Supplementary Fig S1) .
LNCaP-MLuc cells express a secreted Metridia Luciferase (MLuc) which is driven by a β-actin promoter and enhancer to provide a signal that is representative of viable cell numbers (18) . These reporter cells were treated with 400 nM of aptamer-siRNA chimera in the absence of transfection reagents, or transfected with the positive control DNA-PK siRNA. Two days after treatment, cells were irradiated with 2-6 Gy of IR. Cell viability and proliferation was then measured by secreted MLuc activity (Fig 2C) and verified by the commercial Cell Titer-Blue assay (Fig 2D) . Both assays detected significantly enhanced IR-mediated cytotoxicity in 
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stability is required for the systemic application of aptamer-siRNA chimera. Prior to in vivo application, the stability of A10-3-DNAPK chimera were therefore analyzed in media supplemented with mouse or human serum for several days. Results indicate that over half of the chimera remain stable for up to 12 hours at 37 °C ( Supplementary   Fig S2) . Therefore, sufficient chimera should be available for tumor delivery.
The chemically synthesized and annealed chimera were then evaluated as systemic siRNA delivery agents in PSMA-positive and PSMA-negative mouse tumor xenograft models. On two consecutive days, 1 nmol of each chimera was administered intravenously into athymic nude mice hosting established subcutaneous PSMA-positive LNCaP or PSMA-negative PC-3 tumors. Tumors were then harvested for analysis two days post-injection. PSMA-positive LNCaP tumors from mice treated with A10-3-DNAPK had significantly reduced DNA-PK mRNA and protein levels, as quantified by qRT-PCR (Fig 3A) and immunohistochemistry (Fig 3B) , when compared to A10-3-Con treated animals. Targeted DNA-PK mRNA and protein knock-down was further confirmed in LNCaP-MLuc xenograft tumor models ( Supplementary Fig S3) . Conversely, A10-3-DNAPK treatment did not reduce DNA-PK mRNA or protein levels in PSMA-negative PC-3 tumors (Fig 3C-D) .
These results support PSMA-selective targeting by the A10-3-DNA-PK chimera. (Fig 4A) . On the other hand, A10-3-DNAPK treatment did not enhance IR therapy in PSMA-negative PC-3 tumors (Fig 4B) . The tumor volumes of non-irradiated cohorts were similar, indicating that A10-3-DNAPK treatment alone has no significant therapeutic effect in the absence of irradiation for either LNCaP or PC-3 tumors. The combination of A10-3-DNAPK and IR significantly extended the time for PSMA-positive tumor volume quadrupling by approximately 6 weeks, when compared to 3.5 weeks for animals with irradiated tumors that were treated with A10-3-Con control or Neg-DNAPK chimeras (Fig 4C) . This effect was not observed in PSMA-negative PC-3 tumors, indicating PSMA selective radiation sensitization (Fig 4D) . There are several strategies for generating aptamer-siRNA chimera including the continuous in vitro transcription of aptamer-shRNAs, the solid phase synthesis of aptamers and siRNAs followed by complementary annealing, or a combination thereof.
DISCUSSION
The goal of this project was to develop radiation-sensitizing aptamer-siRNA chimera using fully synthesized and annealed components (Fig 1) .
This has previously been accomplished through a similar annealing strategy, where the truncated PSMA aptamer A10-3.2 was extended to include the guide or passenger strand of the siRNA, and the complementary siRNA strand was then separately annealed (15) . Similarly, the addition of complementary sticky bridge sequences to 
aptamers and siRNAs has resulted in successful assembly and fully functional chimera (20) . Here we utilized a region of the 3'-terminus of the A10-3 aptamer as a bridging region for chimera assembly. Complementary sequences were incorporated into the sense siRNA to bridge and join the aptamer, sense and antisense siRNA (Fig   1) . In addition, we intentionally engineered dinucleotide overhangs onto the 3'-ends of both sense and anti-sense siRNAs as previous studies have reported enhanced activity in chimera containing dinucleotide overhangs (15) . Notably, we utilized non-modified RNA for the sense and anti-sense components. Nonetheless, the annealed chimera demonstrated significant stability in human and mouse serum supplemented media (Supplementary Fig S2) , suggesting the aptamer may provide some protection to the conjugated siRNA duplex.
In summary, these data support that the pre-treatment of animals bearing PSMA-positive tumors with chemically synthesized and systemically administered aptamer-siRNA chimeras (two days prior to IR therapy) can significantly enhance tumor IR responses. The experimental design intentionally applied a single non-ablative IR treatment, so that additional therapeutic efficacy from IR-sensitization could be observed. Nonetheless we have observed one animal, treated with A10-3-DNAPK and 6 Gy IR, to have complete tumor ablation for more than three months after the termination of therapy. We anticipate that higher or longer IR doses would have resulted in more long-term tumor responses. Fractionated IR doses may also benefit if longer term gene knock-down is achieved, such as those reported in aptamer-siRNA chimera protective models of HIV transmission (23 Here we sought to develop a first-in-class chemically synthesized IR-sensitizing aptamer-siRNA chimera. This design was pursued to overcome potential hurdles in GMP synthesis associated with plasmid purification, large scale in vitro transcription and full-length product purification of longer aptamer-shRNA chimera (11). We felt that chemical synthesis may be more amendable to larger scale production in a GMP environment. If these chimeras can be safely administered in the clinic, they may enhance a variety of IR therapies for PCa. For example, the chimera could be systemically administered prior to EBRT or brachytherapy for locally advanced PCa.
Similarly, pre-treatment with the chimera may enhance the palliative or cytotoxic potential of systemic radionuclides in the treatment of bone metastatic PCa.
However, such studies would need to be mindful of PSMA expression in non-target tissues, such as in the kidney, to avoid potential IR sensitization of healthy tissues. 
